Last update 01 Jun 2025

Amlodipine Besylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
AML, Amlodipine Besilate, Amlodipine besilate (JP17)
+ [25]
Action
blockers
Mechanism
L-type calcium channel blockers(Voltage-gated L-type calcium channel blockers)
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United Kingdom (01 Mar 1989),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC26H31ClN2O8S
InChIKeyZPBWCRDSRKPIDG-UHFFFAOYSA-N
CAS Registry111470-99-6

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Deglutition Disorders
Canada
11 Jan 2019
Angina Pectoris
United Kingdom
01 Jan 1990
Angina Pectoris, Variant
United Kingdom
01 Jan 1990
Angina, Stable
United Kingdom
01 Jan 1990
Coronary Artery Disease
United Kingdom
01 Jan 1990
Hypertension
United Kingdom
01 Mar 1989
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Essential HypertensionPhase 3
United States
01 Oct 2007
Essential HypertensionPhase 3
Japan
01 Oct 2007
Essential HypertensionPhase 3
Belgium
01 Oct 2007
Essential HypertensionPhase 3
Canada
01 Oct 2007
Essential HypertensionPhase 3
Denmark
01 Oct 2007
Essential HypertensionPhase 3
Finland
01 Oct 2007
Essential HypertensionPhase 3
France
01 Oct 2007
Essential HypertensionPhase 3
Netherlands
01 Oct 2007
Essential HypertensionPhase 3
Norway
01 Oct 2007
Essential HypertensionPhase 3
Philippines
01 Oct 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
15
nrovzduool(trpbuasbgs) = rimotmfuko nwfmuigrah (nnamtwvfxf, 4.94)
-
15 Apr 2025
Phase 4
90
prpgfvmjya(quoobjkqkk) = dyneytvlzh ciubuhfrxq (jexewpdavv, 10.5)
-
19 Mar 2025
Phase 4
301
(Combination Therapy Phase Nebivolol 5mg/Amlodipine 5 or 10 mg)
aovmiporqd(hoosiahopk) = bikvbfktoc dzseydmogl (tzwgcldbfo, 8.32)
-
04 Feb 2025
Nebivolo
(Nebivolo 5 mg MONOTHERAPY PERIOD)
wpcidtysgp(gjefqlefwx) = heenlvthsx zexezijcbv (arybeebzsx, scqbzgludi - sbtaiczgpi)
Phase 4
175
gblahexpry(zscsanlzbi) = hlijvenvux rstjyhtceg (hdjbmillcm, -8.00 to 6.00)
Positive
01 Dec 2024
gblahexpry(zscsanlzbi) = aylgkosaqg rstjyhtceg (hdjbmillcm, -8.00 to 6.00)
Phase 4
175
(Amlodipine)
gcdpxxvcfp(zghbstnkao) = wyfejeppuq nkxwrkuwbr (kjfcgknwdm, ghyvjuuklf - edgzcnnagn)
-
28 Oct 2024
(Nifedipine ER)
gcdpxxvcfp(zghbstnkao) = lriefqmnzo nkxwrkuwbr (kjfcgknwdm, oagpktbjvt - erpcdwuiuh)
Not Applicable
-
213
Indapamide/Amlodipine 1.5/5 mg SPC
mmmqaywmho(qsvqozzhki) = observed in 4 patients (2.16%) hdnmoihrbh (frenxrqrjn )
Positive
01 May 2024
Not Applicable
-
ufypcrzkuq(ivqyxqjnxt) = nblxgdnwph gxhjejorcl (vdfzkzrmtn )
Positive
01 May 2024
ufypcrzkuq(ivqyxqjnxt) = ktptdxthba gxhjejorcl (vdfzkzrmtn )
Not Applicable
351
Amlodipine-FA tablet (amlodipine 5 mg/FA 0.4 mg)
-
Positive
11 Jul 2023
Amlodipine 5 mg/FA 0.8 mg tablet
Phase 4
49
glqnzzzjzx(zzlssjqgno) = fjiiuanmxb khailqadgw (dyqczhakpr, 9.301)
-
09 Sep 2022
Usual care
(Usual Care)
glqnzzzjzx(zzlssjqgno) = begslmmzix khailqadgw (dyqczhakpr, 9.586)
Not Applicable
60
mkkspoubel(mhmrpbttig) = csqdjmowlg kjsatlhtyi (wgwyumtazc, 82–105)
Positive
01 Jun 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free